Sounds like an interesting collaboration ..... and some on here claimed the roadshows would be a big pile of (and I quote) "nothing new" .... looks like that theory is out the window ... lol
GLTAH
https://renovorx.com/
Standard of Care Pancreatic Cancer Treatment May be Ineffective for Treating Tumors and is Often Accompanied by Debilitating Side Effects
The Phase III TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP® (RenovoRx Trans-arterial Micro-perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem™, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy).
The goal of the study has a primary endpoint of overall survival and several secondary endpoints, including quality of life. TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients.
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-19
-
- There are more pages in this discussion • 150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
